EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia

Janna R Shapiro iD, Freda Qi, Karen Colwill, Alina D Dorogy, Ying Liu, Michelle Science, Anne-Claude Gingras, James M Rini, Sumit Gupta iD, Sarah Alexander, Shelly Bolotin iD, Tania H Watts iD

Pediatric Blood & Cancer · 2026-08 · 73 (8)

DOI: 10.1002/1545-5017.70395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 14.05.2026. Verfasst von Janna R Shapiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: COVID-19 Immunity Task Force (Public Health Agency of Canada, the Canadian Immunization Research Network, the University of Toronto. A.C.G. holds the Canada Research Chair in Functional Proteomics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL. Procedure We recruited children with ALL, mostly in the maintenance phase of chemotherapy, and healthy controls who were infected and/or vaccinated with SCV2. Antibody concentrations and avidity against the SCV2 spike (S) protein and its receptor‐binding domain (RBD) were measured, as were the frequencies of S‐specific cytokine‐positive T cells and the concentrations of secreted cytokines.

Results

Antibody levels and avidity were lower in children with ALL than in healthy controls, regardless of when exposure occurred relative to ALL diagnosis. Among children with ALL, vaccination generated greater anti‐RBD antibody levels than infection. Three or more vaccine doses were associated with more robust and higher avidity responses, similar to those of the healthy controls. Antibody levels were more durable in vaccinated children with ALL compared to unvaccinated children. T‐cell responses were similar in healthy controls and children with ALL, although children with ALL showed decreases in the secretion of some cytokines. Among children with ALL, T‐cell responses did not differ by vaccination status and were stable over time.

Conclusions

We identified a significant serological benefit of SCV2 vaccination relative to infection, in terms of antibody avidity, level, and durability. These data can support clinicians in making evidence‐based vaccine recommendations for children with ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaCOVID-19Antibodies, ViralSARS-CoV-2COVID-19 VaccinesHumansChildFemaleMaleChild, PreschoolAdolescentVaccinationInfantT-LymphocytesSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2T cellsacute lymphoblastic leukemiaantibodiesvaccination

Substanzen

Antibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Center for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada.
  • The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
  • Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Ontario, Canada.

ORCID-Profile: Janna R Shapiro, Sumit Gupta, Shelly Bolotin, Tania H Watts

Förderung

  • COVID-19 Immunity Task Force (Public Health Agency of Canada
  • the Canadian Immunization Research Network
  • the University of Toronto. A.C.G. holds the Canada Research Chair in Functional Proteomics

Zitieren

APA

Shapiro, J. R., Qi, F., Colwill, K., Dorogy, A. D., Liu, Y., Science, M., Gingras, A. C., Rini, J. M., Gupta, S., Alexander, S., Bolotin, S., & Watts, T. H. (2026). Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70395

Vancouver

Shapiro JR, Qi F, Colwill K, Dorogy AD, Liu Y, Science M, et al. Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70395

BibTeX
@article{Shapiro2026,
  author = {Shapiro, Janna R and Qi, Freda and Colwill, Karen and Dorogy, Alina D and Liu, Ying and Science, Michelle and Gingras, Anne-Claude and Rini, James M and Gupta, Sumit and Alexander, Sarah and Bolotin, Shelly and Watts, Tania H},
  title = {Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {8},
  doi = {10.1002/1545-5017.70395}
}
Kostenlos starten →